Barinthus Biotherapeutics plc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
United Kingdom
Business Address
20400 CENTURY BLVD, GERMANTOWN, MD, 20874
Mailing Address
20400 CENTURY BLVD, GERMANTOWN, MD, 20874
Phone
44 (0) 1865 818808
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$130.03M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
| 8-K Current report of material events | December 10, 2025 | View on SEC |
| 8-K Current report of material events | November 7, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 7, 2025 | View on SEC |
| 8-K Current report of material events | September 30, 2025 | View on SEC |
| 8-K/A Current report amendment | August 8, 2025 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Pivotal strategic shift initiated by a definitive merger agreement with Clywedog Therapeutics, Inc. on September 29, 2025, aiming to reshape pipeline and strategy.
- Leverages proprietary VACCITECH, SNAPVAX, and SYNTHOLYTIC platforms for innovative immunotherapies and vaccines.
Material Events
8-K
Financial Distress
January 6, 2026
High Impact
- Barinthus Biotherapeutics received a Nasdaq warning letter for failing to maintain a minimum $1.00 stock price for 30 consecutive business days.
- This places the company at risk of delisting from the Nasdaq Global Market.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.